The Lorenzini Foundation in a changing scenario of patient management

Hofmarcher, 2007, Improved health system performance through better care coordination, OECD HEALTH WORKING PAPERS, 30, 1, 10.1787/246446201766 Bodenheimer, 2008, Coordinating care - a perilous journey through the health care system, N Engl J Med, 358, 1064, 10.1056/NEJMhpr0706165 Stuffken, 2008, Association between hospitalization and discontinuity of medication therapy used in the community setting in the Netherlands, Ann Pharmacother, 42, 933, 10.1345/aph.1L062 Leal, 2006, Economic burden of cardiovascular diseases in the enlarged European Union, Eur Heart J, 27, 1610, 10.1093/eurheartj/ehi733 Vlayen, 2008, Atherosclerotic cardiovascular diseases in Belgium: a cost-of-illness analysis, Cardiovasc Drugs Ther, 22, 487, 10.1007/s10557-008-6128-5 Drummond, 2003, Moving beyond the drug budget silo mentality in Europe, Value Health, 6, S74, 10.1046/j.1524-4733.6.s1.8.x Cleland, 2005, Noninva-sive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study, J Am Coll Cardiol, 45, 1654, 10.1016/j.jacc.2005.01.050 Koehler, 2006, Noninvasive home telemonitoring: the Trans-European Network-Home-Care Management System, J Am Coll Cardiol, 48, 850, 10.1016/j.jacc.2006.05.033 Sridhar, 2008, Misfinancing global health: a case for transparency in disbursements and decision making, Lancet, 372, 1185, 10.1016/S0140-6736(08)61485-3 Murray, 2008, Health metrics and evaluation: strengthening the science, Lancet, 371, 1191, 10.1016/S0140-6736(08)60526-7 Backman, 2008, Health systems and the right to health: an assessment of 194 countries, Lancet, 372, 2047, 10.1016/S0140-6736(08)61781-X Marcovina, 2007, Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools, J Intern Med, 261, 214, 10.1111/j.1365-2796.2006.01734.x Erhardt, 2002, Public perceptions of cardiovascular risk in five European countries: the react survey, Int J Clin Pract, 56, 638, 10.1111/j.1742-1241.2002.tb11344.x Cooper, 2008, Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance, BMJ, 336, 1246, 10.1136/bmj.39554.624086.AD Erhardt, 2008, Lipid management in cardiovascular disease prevention guidelines: strategies and tactics for implementation, Atherosclerosis, 196, 532, 10.1016/j.atherosclerosis.2007.05.017 Yood, 2006, Racial differences in reaching target low-density lipopro-tein goal among individuals treated with prescription statin therapy, Am Heart J, 152, 777, 10.1016/j.ahj.2006.02.036 Sokol, 2005, Impact of medication adherence on hospitalization risk and healthcare cost, Med Care, 43, 521, 10.1097/01.mlr.0000163641.86870.af Benner, 2002, Long-term persistence in use of statin therapy in elderly patients, JAMA, 288, 455, 10.1001/jama.288.4.455 Rasmussen, 2007, Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction, JAMA, 297, 177, 10.1001/jama.297.2.177 Schmittdiel, 2008, Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification, J Gen Intern Med, 23, 588, 10.1007/s11606-008-0554-8 Hobbs, 2008, The From The Heart study: a global survey of patient understanding of cholesterol management and cardiovascular risk, and physician-patient communication, Curr Med Res Opin, 24, 1267, 10.1185/030079908X280491 Backlund, 2004, How accurately do general practitioners and students estimate coronary risk in hypercholes-terolaemic patients?, Primary Health Care Research & Development, 5, 145, 10.1191/1463423604pc179oa European Heart Health Charter European Heart Survey on Secondary and Primary Prevention of Coronary Heart Disease Cohen, 2001, ABCs of secondary prevention of CHD: easier said than done, Lancet, 357, 972, 10.1016/S0140-6736(00)04252-5 2001, Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events, Lancet, 357, 995, 10.1016/S0140-6736(00)04235-5 Jones, 2009, Partnering to reduce risks and improve cardiovascular outcomes: American Heart Association initiatives in action for consumers and patients, Circulation, 119, 340, 10.1161/CIRCULATIONAHA.108.191328 World Health Organisation Europe Cooney, 2008, Fourth Joint Taks Force of European Societies' Guidelines on Cardiovascular Disease Prevention in Clinical Practice: A Review, Medicographia, 30, 270 Graham, 2007, Eur J Cardiovasc Prev Rehabil, 14, S1, 10.1097/01.hjr.0000277983.23934.c9